Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Micaela B Reddy"'
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 12, Pp 2675-2686 (2023)
Abstract Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and
Externí odkaz:
https://doaj.org/article/92898601b9704065a9ccb921465d6d65
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/d4c6492f7c014aecab9ead0eb8d945cd
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 11, p e1008424 (2020)
[This corrects the article DOI: 10.1371/journal.pcbi.1007705.].
Externí odkaz:
https://doaj.org/article/366872efe5da4b1eb77da7bd3efa6ebc
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 4, p e1007705 (2020)
Within the human respiratory tract (HRT), virus diffuses through the periciliary fluid (PCF) bathing the epithelium. But virus also undergoes advection: as the mucus layer sitting atop the PCF is pushed along by the ciliated cell's beating cilia, the
Externí odkaz:
https://doaj.org/article/98afc44ee10543f3bacd28f8bda326f8
Autor:
Micaela B. Reddy, Michael B. Bolger, Grace Fraczkiewicz, Laurence Del Frari, Laibin Luo, Viera Lukacova, Amitava Mitra, Joyce S. Macwan, Jim M. Mullin, Neil Parrott, Aki T. Heikkinen
Publikováno v:
Pharmaceutics, Vol 13, Iss 9, p 1325 (2021)
Uridine 5′-diphospho-glucuronosyltransferases (UGTs) are expressed in the small intestines, but prediction of first-pass extraction from the related metabolism is not well studied. This work assesses physiologically based pharmacokinetic (PBPK) mod
Externí odkaz:
https://doaj.org/article/f5e82495484f416fb736034f0fa4ac9c
Autor:
Rodabe N. Amaria, Jordan D. Berlin, Allison S. Harney, Micaela B. Reddy, Carola Berking, Douglas B. Johnson, Matteo S. Carlino, Carla M.L. van Herpen, Filip Y.F.L. De Vos, Michael A. Postow, Paolo A. Ascierto, Jeffrey A. Sosman, Kevin B. Kim, Lisa Zimmer, Martin Schuler
Purpose:Enhanced MAPK pathway signaling and cell-cycle checkpoint dysregulation are frequent in NRAS-mutant melanoma and, as such, the regimen of the MEK inhibitor binimetinib and the selective CDK4/6 inhibitor ribociclib is a rational combination.Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa9203ee81d6cd6053b38bb1b9852e1
https://doi.org/10.1158/1078-0432.c.6532311.v1
https://doi.org/10.1158/1078-0432.c.6532311.v1
Autor:
Rodabe N. Amaria, Jordan D. Berlin, Allison S. Harney, Micaela B. Reddy, Carola Berking, Douglas B. Johnson, Matteo S. Carlino, Carla M.L. van Herpen, Filip Y.F.L. De Vos, Michael A. Postow, Paolo A. Ascierto, Jeffrey A. Sosman, Kevin B. Kim, Lisa Zimmer, Martin Schuler
Supplementary Table from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f2f2bf48944ea382e33195f83ce5ffb
https://doi.org/10.1158/1078-0432.22486413
https://doi.org/10.1158/1078-0432.22486413
Autor:
Rodabe N. Amaria, Jordan D. Berlin, Allison S. Harney, Micaela B. Reddy, Carola Berking, Douglas B. Johnson, Matteo S. Carlino, Carla M.L. van Herpen, Filip Y.F.L. De Vos, Michael A. Postow, Paolo A. Ascierto, Jeffrey A. Sosman, Kevin B. Kim, Lisa Zimmer, Martin Schuler
Supplementary Figure from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eadd5e9e26dee65c8295a0358ab6ef2
https://doi.org/10.1158/1078-0432.22486419.v1
https://doi.org/10.1158/1078-0432.22486419.v1
Autor:
Martin Schuler, Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow, Filip Y.F.L. De Vos, Carla M.L. van Herpen, Matteo S. Carlino, Douglas B. Johnson, Carola Berking, Micaela B. Reddy, Allison S. Harney, Jordan D. Berlin, Rodabe N. Amaria
Publikováno v:
Clinical Cancer Research, 28, 14, pp. 3002-3010
Clinical Cancer Research, 28, 3002-3010
Clinical Cancer Research, 28, 3002-3010
Purpose: Enhanced MAPK pathway signaling and cell-cycle checkpoint dysregulation are frequent in NRAS-mutant melanoma and, as such, the regimen of the MEK inhibitor binimetinib and the selective CDK4/6 inhibitor ribociclib is a rational combination.
Autor:
Tamara D. Cabalu, Mengyao Li, Kenichi Umehara, Dermot F. McGinnity, Neil Parrott, Kunal S Taskar, Arian Emami Riedmaier, Micaela B Reddy, Hugues Chanteux, Martin E. Dowty, Justine Badée, Jialin Mao, Jayaprakasam Bolleddula, Loeckie de Zwart, Jessica Rehmel, Dwaipayan Mukherjee, Chandra Prakash, Niresh Hariparsad, Masakatsu Kotsuma, Diane Ramsden, Karthik Venkatakrishnan, Venkatesh Pilla Reddy, Kushal Shah
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:770-781
The International Consortium for Innovation and Quality (IQ) Physiologically Based Pharmacokinetic (PBPK) Modeling Induction Working Group (IWG) conducted a survey across participating companies around general strategies for PBPK modeling of inductio